Ideaya Biosciences Advances with IDE892 Study Targeting MTAP-Deleted Tumors

Ideaya Biosciences (IDYA) announced an update on their ongoing clinical study.

Ideaya Biosciences is conducting a clinical study titled A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors. The study aims to assess the safety, efficacy, and pharmacokinetics of IDE892, both as a standalone treatment and in combination with IDE397, in patients with MTAP-deleted advanced solid tumors. This research is significant as it targets a specific genetic deletion, potentially offering new treatment avenues for various cancers.

The interventions being tested are IDE892, a PRMT5 inhibitor, and IDE397, a MAT2A inhibitor. IDE892 is intended to treat advanced or metastatic cancers with MTAP deletions, while IDE397 is evaluated in combination with IDE892 to enhance therapeutic effects.

The study is designed as an interventional trial with a non-randomized, sequential model. There is no masking, and the primary purpose is treatment. The study includes dose escalation and expansion phases to determine the optimal dosage and assess antitumor activity.

The study’s timeline indicates that it is not yet recruiting, with the initial submission date on November 13, 2025, and the last update on December 9, 2025. These dates are crucial as they mark the study’s progress and readiness to begin participant recruitment.

The market implications of this study update could be significant for Ideaya Biosciences, potentially influencing its stock performance positively if the study results are favorable. The focus on MTAP-deleted tumors could set Ideaya apart in the oncology market, where targeted therapies are increasingly valued.

The study is ongoing, with further details available on the ClinicalTrials portal.

To learn more about IDYA’s potential, visit the Ideaya Biosciences drug pipeline page.